Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Therapix Biosciences — Investor Presentation (September 2020)
22 slides from Scisparc's investor presentation, Sep 16, 2020
Slide 1: Developing cannabinoid based pharmaceuticals Corporate Presentation September 2020
Developing cannabinoid based pharmaceuticals Corporate Presentation • September 2020
Slide 2: Safe Harbor Statement
Saf e Harbo r Statement This presentation of Therapix Biosciences Ltd . (the “Company”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws . Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seek
Slide 3: Our Vision
To bridge Cannabis and cannabinoids to the healthcare system to improve the health and wellbeing of patients OUR VISION
Slide 4: Therapix Company Highlights
• D eveloping cannabinoid - based therapies • Science driven and targeted treatment solutions • New, committed experienced managment • Entourage Effect seeks to increase efficiency, lower dosage and side effects • Our intellectual property portfolio comprises three granted U.S. patents and pending p
Slide 5: The Therapix Story
The Therapix S tory Therapix is a s pecialty p harmaceutical c ompany focused on repurposing approved c annabinoids for new indications Platform Programs THX - 110 An innovative and proprietary drug candidate platform based on FDA approved THC, for the treatment of Central Nervous System diseases su
Slide 6: The Entourage Effect
T h e “ Entourag e Effect ” The "Entourage Effect", first described by Prof. Raphael Mechoulam in 1998 Effects of the Endocannabinoid system can be explained by its overall constituents working together, synergistically, rather to any single component The Entourage technology is the basis of all t
Slide 7: The Entourage Effect Therapix Platform
“ The Entourage Effect “ Therapix Platform Increased Efficiency, Lower Dosage and Side Effects Therapix ’ s proprietary combination of CannAmide TM and any Cannabinoid creating an “ Entourage Effect ” , first discovered by Prof. Raphael Mechoulam in 1998 , which results in synergy. CannAmide TM Form
Slide 8: Dosage regimen compromises therapeutic benefits of cannabis
Dosage regiment compromises therapeutic benefits of cannabis and severely impacts treatment • Serious diminishing effect over time and extensive use • High doses lead to unwanted adverse events • Compromises therapeutic benefits of cannabis and severely impacts treatment We believe that reducing med
Slide 9: Tourette Syndrome Disease Overview & Clinical Features
Disease Overview • TS is a movement and neurobehavioral disorder characterized by motor and vocal chronic tics with onset before age 18 • About half to two - thirds of the cases get much better during adolescence 1 • However adults will generally be more severe patients 2 • Tics may be associated wi
Slide 10: Tourette Syndrome Phase IIa Clinical Trial
Tourette Syndrome Phase IIa Clinical Trial THX - 110 S: Seeking to Provide Increased Efficiency, Lower Dosage and Side Effects Tourette syndrome is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co - morbidities We believe that topline results
Slide 11: Tourette Syndrome Phase IIb Clinical Trial
Joint Pharma Tourette Syndrome Phase IIb Clinical Trial • Therapix intends to evaluate the efficacy, safety and tolerability of its THX - 110 C (Full Cannabis Extract (FCE) with CannAmide TM ) in a randomized, placebo controlled trial • The study is expected to commence in at least on center in Hano
Slide 12: THX-110 for Obstructive Sleep Apnea
THX - 110 s for OBSTRUCTIVE SLEEP APNEA THX - platform: Seeking to Provide Increased Efficiency, Lower Dosage and Side Effects OSA causes breathing to repeatedly stop during sleep and is a potentially lethal sleep disorder. There are currently no FDA approved pharmaceutical therapies to treat
Slide 13: Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA) • Of the 10 patients recruited into the study, nine patients have completed the study and one has dropped out of the study due to treatment associated adverse event (dizziness) • Among the remaining nine patients, 55 % demonstrated significant improvement in Apnea – Hyp
Slide 14: THX-210 for Autism: PEA Increases CBD Effects
PEA Significantly Increases CBD Effects 1 • CBD was shown to prevent fat accumulation in liver cells in a concentration dependent manner • PEA by itself didn ’ t affect fat accumulation • Addition of PEA to CBD reduced the required CBD concentration while achieving maximal effect THX - 210 for Autis
Slide 15: THX-160 for Pain
1 • An innovative and proprietary CB 2 Receptor Agonist formulation intended for the treatment of pain. This specific CB 2 receptor agonist was synthesized by Professor Raphael Mechoulam, Ph.D. • THX - 160 , a synthetic CB 2 Receptor Agonist, which is protected under patent granted in the US and Eur
Slide 16: CannAmide (TheraPEA)
CannAmide ™ CannAmide TM (TheraPEA) – For pain and inflammation: Active ingredient Palmitoylethanolamide – Endocannabinoid - like compound, a lipid - messenger and an endogenous neuromodulator with a broad spectrum of pharmacological properties and can be found naturally in the body, as well as in e
Slide 17: Pipeline
Pipe l ine COMPOUND THX – 110 THERAPEUTIC AREA PRECLINICAL Medical Cannabis route PHASE IIa PHASE IIb TOURETTE SYNDROME OBSTRUCTIVE SLEEP APNEA THX – 110 THX – 210 Autism THX – 160 Pain THX - 110 – Full Cannabis Extract (FCE) with CannAmide TM for the treatment Tourette ’ s Syndrome and Obstructive
Slide 18: Highlights
• We believe that we have u nique technologies in the cannabis market • Focus on cannabinoid family products with unique combinations, methods of administrations and formulations • Pursuing new high potential R&D and clinical programs through M&A • Advanced clinical programs • CannAmide TM supplemen
Slide 19: Therapix Management
Joint Pharma Therapix Management Adi Zuloff - shani , PhD, CTO Dr. Adi Zuloff - Shani has served as our Chief Technologies Officer since February 2016 . Dr. Zuloff - Shani A Research and Development professional with an overall experience of about 20 years in the bio - tech industry, in start - ups
Slide 20: Board of Directors
Joint Pharma Board of Directors Mr. Amitay Weiss , D i r e c t o r currently serves as chairman of the board of directors of P.L.T Financial Services Ltd., as chairman of the board of directors of Matomy Media Group Ltd. and as an external director of Cofix Group Ltd. In 2016 , Mr. Weiss founded Ami
Slide 21: Scientific Advisory Board
Therapix Biosciences Scientific Advisory Board Active scientists CNS Endocannabinoids and PEA Pain Dr. Michael Bloch Prof. James Leckman Prof. Raphael Mechoulam Prof. Avi Weizman Prof. Kirsten Muller - Vahl Prof. Michael Davidson Prof. Elon Eisenberg Dr. Daniele Piomelli Prof. Saoirse. O'Sullivan Dr
Slide 22: Thank you
THERAP DX | tank you
Therapix Biosciences — Investor Presentation (September 2020) on 6ix